CLINICAL TRIALS PROFILE FOR BUCINDOLOL

Clinical Trials for Bucindolol

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00000560 ↗	Beta-Blocker Evaluation in Survival Trial (BEST)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	To determine if addition of a beta-blocker to standard therapy in Class III and Class IV heart failure patients reduced total mortality.
NCT00832442 ↗	Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure	Unknown status	University of Oxford		Several large trials have shown that beta-blocker treatment reduces the risk of death and hospital admission in patients with symptomatic heart failure. Unfortunately, survey data suggests relatively poor utilisation of beta-blockers, despite ample evidence for good tolerability. Additionally there are several important unanswered questions, such as clinical efficacy for specific sub-populations (women, the elderly and patients with diabetes or other co-morbidities) and the effect of beta-blockers in combination with other medications. Previous meta-analyses, based on published tabular data, have been conducted although this approach has important biases and limitations. We plan to perform a carefully conducted systematic review of individual patient data from the major randomised trials of beta-blockers in heart failure. The goals of this collaborative project are to clarify the overall efficacy of beta-blockers and identify sub-groups that show particular benefit, thereby increasing the use of beta-blockers, reducing adverse clinical outcomes and the high costs associated with this condition.
NCT00832442 ↗	Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure	Unknown status	Royal Brompton & Harefield NHS Foundation Trust		Several large trials have shown that beta-blocker treatment reduces the risk of death and hospital admission in patients with symptomatic heart failure. Unfortunately, survey data suggests relatively poor utilisation of beta-blockers, despite ample evidence for good tolerability. Additionally there are several important unanswered questions, such as clinical efficacy for specific sub-populations (women, the elderly and patients with diabetes or other co-morbidities) and the effect of beta-blockers in combination with other medications. Previous meta-analyses, based on published tabular data, have been conducted although this approach has important biases and limitations. We plan to perform a carefully conducted systematic review of individual patient data from the major randomised trials of beta-blockers in heart failure. The goals of this collaborative project are to clarify the overall efficacy of beta-blockers and identify sub-groups that show particular benefit, thereby increasing the use of beta-blockers, reducing adverse clinical outcomes and the high costs associated with this condition.
NCT01970501 ↗	Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure	Completed	Medtronic	Phase 2	This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.
NCT01970501 ↗	Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure	Completed	ARCA Biopharma, Inc.	Phase 2	This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.

Clinical Trial Conditions for Bucindolol

Condition Name

Condition Name
Intervention	Trials
Heart Failure	2
Cardiovascular Diseases	1
Current or Recent History of Atrial Fibrillation	1
Heart Diseases	1

Condition MeSH

Condition MeSH
Intervention	Trials
Heart Failure	3
Cardiovascular Diseases	1
Atrial Flutter	1
Atrial Fibrillation	1

Clinical Trial Locations for Bucindolol

Trials by Country

Trials by Country
Location	Trials
United States	27
Canada	5
United Kingdom	1
Netherlands	1
Hungary	1

Trials by US State

Trials by US State
Location	Trials
Colorado	1
California	1
Arizona	1
Alaska	1
Washington	1

Clinical Trial Progress for Bucindolol

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	2
Unknown status	1

Clinical Trial Sponsors for Bucindolol

Sponsor Name

Sponsor Name
Sponsor	Trials
National Heart, Lung, and Blood Institute (NHLBI)	1
University of Oxford	1
Royal Brompton & Harefield NHS Foundation Trust	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Other	2
Industry	2
NIH	1